Anticoagulant therapy in cerebral infarction

Publisher Website
Google Scholar
Abstract
Judging from the data, it can be concluded that, from the standpoint of mortality, longterm anticoagulant therapy plays no beneficial role in the treatment of thrombotic cerebrovascular disease and may be harmful. Insofar as transient ischemic attacks and progression of infarction are reduced in the categories of transient ischemic attack and thrombosis-in-evolution and the mortality in the 2 groups is not significantly different, anticoagulant therapy may be worthwhile on a short-term basis[long dash]possibly four to six months rather than indefinitely. In the treated group, there were 12 fatal hemorrhagic complications and hemorrhage contributed to a fatal outcome in a few further cases. There were 2 instances of nonfatal intracerebral bleeding in the treated group and 1 in the control. Patients were almost without exception from the wards and outpatient clinics, and many obstacles to satisfactory long-term management arise under these circumstances. Possibly in private practice uncertainty of diagnosis may be less and, with close personal supervision, anticoagulant accidents may be lowered.

This publication has 1 reference indexed in Scilit: